State lawmakers will continue to focus on the cost of prescription drugs as the 2020 legislative season gets underway, potentially advancing measures to require the disclosure of manufacturer drug pricing information and bills to limit or eliminate the role PBMs play in state Medicaid programs.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.